|
Effect of CTLA-4 overexpression on response to ipilimumab in melanoma. |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
Patents, Royalties, Other Intellectual Property - OmniSeq (Inst) |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche/Genentech |
Travel, Accommodations, Expenses - Amgen; Merck |
|
|
Stock and Other Ownership Interests - GE Healthcare |
Consulting or Advisory Role - Bristol-Myers Squibb; Celyad; Lion Biotechnologies; Omniseq |
Research Funding - Alkermes (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merrimack (Inst) |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
Patents, Royalties, Other Intellectual Property - OmniSeq (Inst) |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
Patents, Royalties, Other Intellectual Property - OmniSeq (Inst) |
|
Antonios Papanicolau-Sengos |
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
|
|
Employment - OmniSeq; Thermo Fisher Scientific |
|
Stock and Other Ownership Interests - OmniSeq; Thermo Fisher Scientific |
Patents, Royalties, Other Intellectual Property - OmniSeq (Inst); Thermo Fisher Scientific (Inst) |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - OmniSeq |
Honoraria - NanoString Technologies |
Consulting or Advisory Role - NanoString Technologies |
Patents, Royalties, Other Intellectual Property - OmniSeq (Inst) |